Skip to main content
OTCMKTS:MPSYF

MorphoSys Stock Forecast, Price & News

$93.05
0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$93.05
$93.05
50-Day Range
$88.15
$99.95
52-Week Range
$88.15
$140.65
VolumeN/A
Average Volume3,800 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MPSYF News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.


MorphoSys logo

About MorphoSys

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MPSYF
CUSIPN/A
CIKN/A
Phone49 89 89927 0
Employees615
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1952nd out of 2,044 stocks

Biotechnology Industry

139th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











MorphoSys (OTCMKTS:MPSYF) Frequently Asked Questions

Is MorphoSys a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MorphoSys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MPSYF, but not buy additional shares or sell existing shares.
View analyst ratings for MorphoSys
or view top-rated stocks.

What stocks does MarketBeat like better than MorphoSys?

Wall Street analysts have given MorphoSys a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MorphoSys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:
  • Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 56, Pay $2.5M)
  • Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 59, Pay $1.43M)
  • Dr. Roland Wandeler Ph.D., COO & Member of Management Board (Age 49, Pay $1.44M)
  • Mr. Sung H. Lee, CFO & Member of Management Board (Age 51)
  • Mr. Klaus De Wall, Head of Accounting & Tax
  • Ms. Lara Smith Weber, Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban, Head of Discovery Alliances & Technologies
  • Dr. Anja Pomrehn, Sr. VP & Head of Investor Relations
  • Dr. Armin Weidmann, Head of Compliance and Quality Assurance
  • Ms. Charlotte Lohmann, Sr. VP & Gen. Counsel (Age 51)

Who are some of MorphoSys' key competitors?

What is MorphoSys' stock symbol?

MorphoSys trades on the OTCMKTS under the ticker symbol "MPSYF."

How do I buy shares of MorphoSys?

Shares of MPSYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MorphoSys' stock price today?

One share of MPSYF stock can currently be purchased for approximately $93.05.

How many employees does MorphoSys have?

MorphoSys employs 615 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.com.

How can I contact MorphoSys?

The company can be reached via phone at 49 89 89927 0.


This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.